Connect Biopharma Holdings Limited (CNTB)
| Market Cap | 57.07M -43.7% |
| Revenue (ttm) | 2.95M +50.3% |
| Net Income | -68.99M |
| EPS | -1.19 |
| Shares Out | 62.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,517,292 |
| Open | 0.8937 |
| Previous Close | 0.9090 |
| Day's Range | 0.8800 - 0.9284 |
| 52-Week Range | 0.8501 - 3.8200 |
| Beta | -0.18 |
| Analysts | Strong Buy |
| Price Target | 5.88 (+548.86%) |
| Est. Earnings | Nov 11, 2026 |
About CNTB
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Financial Performance
In 2025, CNTB's revenue was $64,000, a decrease of -99.75% compared to the previous year's $26.03 million. Losses were -$55.48 million, 255.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price target is $5.88, which is an increase of 548.86% from the latest price.
News
Connect Biopharma assumed with an Outperform at Leerink
Leerink assumed coverage of Connect Biopharma (CNTB) with an Outperform rating and $4 price target The firm notes Connect Biopharma offers exposure to an interleukin-4 receptor alpha in acute exacerba...
3 Penny Stocks on Investors’ Radar, October 1
Generation Essentials Group ($TGE), Tenon Medical ($TNON), and Connect Biopharma Holdings ($CNTB) are among the penny stocks to watch on October 1, according to TipRanks’ Penny Stock Screener Tool. A ...
Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?
Connect Biopharma stock rallied over 98% after the company announced new clinical trial data for rademikibart.
Connect Biopharma Holdings Transcript: Study result
The Seabreeze STAT COPD study showed rademikibart significantly reduced treatment failures, exacerbations, and hospital/ED visits after COPD exacerbations, with robust safety and strong health economic potential. Plans include further regulatory engagement, expanded U.S. enrollment, and IV formulation development.
Connect Biopharma Holdings Press release: Study result
Connect Biopharma Holdings issued a press release on September 30, 2026, disclosing material business information to investors.
Connect Biopharma Holdings Slides: Study result
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Connect Biopharma announces results from global Phase 2 study of rademikibart
Connect Biopharma (CNTB) announced topline results from its global Phase 2 study evaluating rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha ant...
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Connect Biopharma price target lowered to $5 from $8 at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed lowered the firm’s price target on Connect Biopharma (CNTB) to $5 from $8 and keeps an Outperform rating on the shares. The firm believes the Phase…
Connect Biopharma price target lowered to $6 from $7 at Canaccord
Canaccord analyst Edward Nash lowered the firm’s price target on Connect Biopharma (CNTB) to $6 from $7 and keeps a Buy rating on the shares. The firm updated its model…
Connect Biopharma Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Seabreeze asthma data showed rapid, significant lung function improvement and validated prior findings, supporting phase III advancement. U.S. claims data reveal a large, economically significant acute asthma market, while regulatory discussions will focus on FEV1 as a primary endpoint.
Connect Biopharma Holdings Transcript: Study result
The Seabreeze STAT asthma study showed rademikibart rapidly improved airway function and reduced treatment failures, with a significant FEV1 benefit at day seven. The drug was well-tolerated, and findings support advancing to phase III with FEV1 as a key endpoint.
Connect Biopharma Holdings Press release: Study result
Connect Biopharma Holdings issued a press release on September 15, 2026, disclosing material business information to investors.
Connect Biopharma Holdings Slides: Study result
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day ...
Connect Biopharma Holdings Slides: Corporate presentation
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans...
Connect Biopharma price target raised to $7 from $6 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Connect Biopharma (CNTB) to $7 from $6 and keeps a Buy rating on the shares. The firm updated its model…
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – ...
Connect Biopharma Holdings Earnings release: Q2 2026
Connect Biopharma Holdings released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Connect Biopharma Holdings Quarterly report: Q2 2026
Connect Biopharma Holdings has published its Q2 2026 quarterly earnings report on August 12, 2026.
Connect Biopharma Holdings Slides: Corporate presentation
Connect Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Connect Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Connect Biopharma (CNTB) with an Outperform rating and $8 price target Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 a...
Connect Biopharma initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Connect Biopharma (CNTB) with an Overweight rating and $7 price target The firm cites rademikibart’s “differentiated mechanism” and potentially unique position as t...
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet w...